Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00788307 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00788307: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT00788307 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00788307, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
RATIONALE: Radioactive drugs, such as radioactive iodine, may carry radiation directly to tumor cells and not harm normal cells. Placing a gene called Ad5CMV-NIS in prostate cancer cells may help the prostate cells take in more radioactive iodine and thus kill the cancer cells. Drugs, such as liothyronine sodium, may protect the thyroid from the side effects of radioactive iodine. PURPOSE: This phase I trial is studying the side effects and best dose of gene therapy given together with radioactive iodine in treating patients with locally recurrent prostate cancer that did not respond to external-beam radiation therapy.
Interventions
- OTHER laboratory biomarker analysis
- GENETIC reverse transcriptase-polymerase chain reaction
- RADIATION iodine I 131
- DRUG liothyronine sodium
- BIOLOGICAL Ad5-CMV-NIS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-11-03 |
| Est. Completion | 2018-02-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00788307
The ClinicalTrials.gov registry entry for NCT00788307 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00788307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00788307 about?
NCT00788307 is a clinical study titled "Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy". RATIONALE: Radioactive drugs, such as radioactive iodine, may carry radiation directly to tumor cells and not harm normal cells. Placing a gene called Ad5CMV-NIS in prostate cancer cells may help the prostate cells take in more radioactive iodine and thus kill the cancer cells. Drugs, such as liothy...
What is the current status of trial NCT00788307?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2008-11-03. Estimated completion is 2018-02-07.
What interventions are being tested in trial NCT00788307?
The interventions under investigation include: laboratory biomarker analysis (OTHER), reverse transcriptase-polymerase chain reaction (GENETIC), iodine I 131 (RADIATION), liothyronine sodium (DRUG), Ad5-CMV-NIS (BIOLOGICAL).
Who is sponsoring clinical trial NCT00788307?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.